Key result
The ACCOMPLISH trial will randomize 12,600 hypertensive patients to amlodipine/benazapril or benazapril/hydrochlorothiazide to detect a 15% relative reduction in cardiovascular events over 5 years.
Why the study?
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
RCT (n=12,600)
Blinded
Randomized
Yes
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
The ACCOMPLISH trial is designed to prospectively compare the effects of two first-line antihypertensive combination therapies (amlodipine/benazapril vs benazapril/hydrochlorothiazide) on hard cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Supports initial CCB-inclusive combinations for BP control; reinforces guideline recommendations from RCT evidence.
Jamerson et al. (2004) conducted an RCT in Hypertension (n=12,600). Amlodipine besylate/benazapril vs. Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg, can be further titrated to 40/25 mg) was evaluated on Composite of cardiovascular mortality and morbidity. The ACCOMPLISH trial will randomize 12,600 hypertensive patients to amlodipine/benazapril or benazapril/hydrochlorothiazide to detect a 15% relative reduction in cardiovascular events over 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: